WWE star’s company inks deal with Baywood to market energy drink
SCOTTSDALE, Ariz. Baywood International last week announced an agreement with Layfield Inc. to create and distribute specialty beverages as early as next month.
The companies have jointly formed Layfield Energy and will roll out their first product through major retail outlets and direct to consumer via a dedicated website. “I know how to make a big splash and, believe me, we will make a huge one” stated John Layfield, principal of Layfield and WWE Smackdown star. “I have endorsed several products over the years, and now I am truly thrilled about being involved with my own project. I am not only going to be endorsing the product, but I will be running the company full time with the great management at Baywood.”
Reckitt Benckiser makes $2.3 billion offer for Adams
CHESTER, N.J. Reckitt Benckiser Group on Friday commenced its previously announced cash tender offer for all of the outstanding shares of Adams Respiratory Therapeutics in a deal that would be worth $2.3 billion, first announced Dec. 10.
The deal will expire if not approved by Adams’ shareholders by Jan. 23.
The offer is being made through Twickenham, a wholly-owned subsidiary of Reckitt Benckiser. Adams’ board has unanimously determined that the offer is fair to and in the best interests of Adams’ stockholders and recommended that holders of Adams common stock accept the offer and tender their shares in the offer.
NAD finds in favor of Relaxane’s ad claims
NEW YORK The National Advertising Division of the Council of Better Business Bureaus has determined that advertising claims for Relaxane, a dietary supplement advertised by Indegene Pharmaceuticals to relieve the symptoms of stress, are supported by the evidence provided by the advertiser.
NAD examined labeling claims and Internet claims that included:
- “For the first time—a clinically tested non-addictive product that relieves the symptoms of everyday stress.”
- “Relaxane is effective in managing everyday stress, it alleviates multiple symptoms of everyday stress—frustration, irritability, restlessness, stress-related gastrointestinal discomforts (fullness, bloating, cramps) and stress-related minor muscle pain.”
- “Relaxane is designed to provide stress relief and address multiple symptoms of stress.”
- “Relaxane is an innovative stress reducer, clinically tested, optimized plant-derived Natural molecular composition of valeriana officinalis, melissa officinalis, passiflora incarnata and petasites hybridus that work on the multiple symptoms of stress.”
The advertiser presented as evidence three studies performed on the product.
Following its review of the evidence, NAD was satisfied that the challenged advertising clearly conveys that Relaxane is for, and has been tested for, relief and alleviation of the symptoms associated with stress. NAD determined as well that the advertiser provided a reasonable basis for a claim that Relaxane, when taken as directed, is non-addictive.
Indigene Pharmaceuticals, in its advertiser’s statement, said the company is pleased that NAD has found that claims for Relaxane are substantiated. “In particular,” the company stated, “Indigene Pharmaceuticals, is pleased that NAD has found that clinical testing on a Relaxane product itself is the gold standard for supporting advertising claims.”
NAD, the advertising industry’s self-regulatory forum, has expanded its review of dietary-supplement advertising, pursuant to a series of grants made by the Council for Responsible Nutrition.